AKT1 and cancer: It is well acknowledged that activation of AKT, the major downstream effecter of PI3K, is frequently observed in human tumors (Brugge et al., 2007; Yu et al., 2012), and the activation of AKT promotes the development of cancer as well as resistance to chemotherapy and radiation therapy.